{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T07:47:44Z","timestamp":1787471264877,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>RNA-binding motif protein 39 (RBM39), as a key factor in tumor-targeted mRNA and protein expression, not only plays a vital role in tumorigenesis, but also has broad development prospects in clinical treatment and drug research. Moreover, since RBM39 was identified as a target of sulfonamides, it has played a key role in the emerging field of molecule drug development. Hence, it is of great significance to study the interaction between RBM39 and tumors and the clinical application of drug-targeted therapy. In this paper, we describe the possible multi-level regulation of RBM39, including gene transcription, protein translation, and alternative splicing. Importantly, the molecular function of RBM39 as an important splicing factor in most common tumors is systematically outlined. Furthermore, we briefly introduce RBM39\u2019s tumor-targeted drug research and its clinical application, hoping to give reference significance for the molecular mechanism of RBM39 in tumors, and provide reliable ideas for in-depth research for future therapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41420-021-00598-7","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T13:04:54Z","timestamp":1628859894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["RNA-binding protein 39: a promising therapeutic target for cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"Caipeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"598_CR1","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1172\/JCI116848","volume":"92","author":"H Imai","year":"1993","unstructured":"Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Investig. 1993;92:2419\u201326.","journal-title":"J Clin Investig"},{"key":"598_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2004.12.025","volume":"17","author":"DH Dowhan","year":"2005","unstructured":"Dowhan DH, Hong EP, Auboeuf D, Dennis AP, Wilson MM, Berget SM, et al. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol Cell. 2005;17:429\u201339.","journal-title":"Mol Cell"},{"key":"598_CR3","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1007\/s13277-014-1819-y","volume":"35","author":"Y Chai","year":"2014","unstructured":"Chai Y, Liu X, Dai L, Li Y, Liu M, Zhang JY. Overexpression of HCC1\/CAPER\u03b1 may play a role in lung cancer carcinogenesis. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35:6311\u20137.","journal-title":"Tumour Biol J Int Soc Oncodev Biol Med"},{"key":"598_CR4","doi-asserted-by":"publisher","first-page":"30340","DOI":"10.18632\/oncotarget.25719","volume":"9","author":"MC Campbell","year":"2018","unstructured":"Campbell MC, Pontiggia L, Russell AY, Schwarting R, Camacho J, Jasmin JF, et al. CAPER as a therapeutic target for triple negative breast cancer. Oncotarget 2018;9:30340\u201354.","journal-title":"Oncotarget"},{"key":"598_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13402-012-0088-2","volume":"35","author":"AH Sillars-Hardebol","year":"2012","unstructured":"Sillars-Hardebol AH, Carvalho B, Beli\u00ebn JA, de Wit M, Delis-van Diemen PM, Tijssen M, et al. CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression. Cell Oncol. 2012;35:293\u2013300.","journal-title":"Cell Oncol"},{"key":"598_CR6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.4161\/cc.28156","volume":"13","author":"I Mercier","year":"2014","unstructured":"Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, et al. CAPER, a novel regulator of human breast cancer progression. Cell Cycle. 2014;13:1256\u201364.","journal-title":"Cell Cycle"},{"key":"598_CR7","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1038\/s41418-020-0541-0","volume":"27","author":"N Lalaoui","year":"2020","unstructured":"Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L, et al. Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death Differ. 2020;27:2768\u201380.","journal-title":"Cell Death Differ"},{"key":"598_CR8","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1128\/JVI.00903-08","volume":"82","author":"J Dutta","year":"2008","unstructured":"Dutta J, Fan G, G\u00e9linas C. CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel\/NF-kappaB oncoprotein v-Rel. J Virol. 2008;82:10792\u2013802.","journal-title":"J Virol"},{"key":"598_CR9","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/cncr.26488","volume":"118","author":"G Huang","year":"2012","unstructured":"Huang G, Zhou Z, Wang H, Kleinerman ES. CAPER-\u03b1 alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cells. Cancer 2012;118:2106\u201316.","journal-title":"Cancer"},{"key":"598_CR10","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1093\/nar\/gky389","volume":"46","author":"J Kr\u00e1lovicov\u00e1","year":"2018","unstructured":"Kr\u00e1lovicov\u00e1 J, \u0160evc\u00edkov\u00e1 I, Stejskalov\u00e1 E, Obuca M, Hiller M, Stanek D, et al. PUF60-activated exons uncover altered 3\u2019 splice-site selection by germline missense mutations in a single RRM. Nucleic Acids Res. 2018;46:6166\u201387.","journal-title":"Nucleic Acids Res"},{"key":"598_CR11","doi-asserted-by":"publisher","first-page":"17325","DOI":"10.1074\/jbc.M114.558825","volume":"289","author":"S Loerch","year":"2014","unstructured":"Loerch S, Maucuer A, Manceau V, Green MR, Kielkopf CL. Cancer-relevant splicing factor CAPER\u03b1 engages the essential splicing factor SF3b155 in a specific ternary complex. J Biol Chem. 2014;289:17325\u201337.","journal-title":"J Biol Chem"},{"key":"598_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/mol.108.050963","volume":"75","author":"G Lebon","year":"2009","unstructured":"Lebon G, Langmead CJ, Tehan BG, Hulme EC. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol Pharmacol. 2009;75:331\u201341.","journal-title":"Mol Pharmacol"},{"key":"598_CR13","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1128\/MCB.25.8.2969-2980.2005","volume":"25","author":"D Cazalla","year":"2005","unstructured":"Cazalla D, Newton K, C\u00e1ceres JF. A novel SR-related protein is required for the second step of pre-mRNA splicing. Mol Cell Biol. 2005;25:2969\u201380.","journal-title":"Mol Cell Biol"},{"key":"598_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1074\/jbc.M110417200","volume":"277","author":"DJ Jung","year":"2002","unstructured":"Jung DJ, Na SY, Na DS, Lee JW. Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. J Biol Chem. 2002;277:1229\u201334.","journal-title":"J Biol Chem"},{"key":"598_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1101\/gr.473902","volume":"12","author":"J Rappsilber","year":"2002","unstructured":"Rappsilber J, Ryder U, Lamond AI, Mann M. Large-scale proteomic analysis of the human spliceosome. Genome Res. 2002;12:1231\u201345.","journal-title":"Genome Res"},{"key":"598_CR16","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1073\/pnas.0400782101","volume":"101","author":"AI Su","year":"2004","unstructured":"Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004;101:6062\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"598_CR17","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/s41418-018-0239-8","volume":"26","author":"I Schulien","year":"2019","unstructured":"Schulien I, Hockenjos B, Schmitt-Graeff A, Perdekamp MG, Follo M, Thimme R, et al. The transcription factor c-Jun\/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. Cell Death Differ. 2019;26:1688\u201399.","journal-title":"Cell Death Differ"},{"key":"598_CR18","doi-asserted-by":"publisher","first-page":"e9983","DOI":"10.1371\/journal.pone.0009983","volume":"5","author":"M Ramakrishna","year":"2010","unstructured":"Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PloS ONE. 2010;5:e9983.","journal-title":"PloS ONE"},{"key":"598_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.bbagrm.2016.06.007","volume":"1859","author":"S Mai","year":"2016","unstructured":"Mai S, Qu X, Li P, Ma Q, Cao C, Liu X. Global regulation of alternative RNA splicing by the SR-rich protein RBM39. Biochim Biophys Acta. 2016;1859:1014\u201324.","journal-title":"Biochim Biophys Acta"},{"key":"598_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bbrc.2016.03.108","volume":"473","author":"S Mai","year":"2016","unstructured":"Mai S, Qu X, Li P, Ma Q, Liu X, Cao C. Functional interaction between nonreceptor tyrosine kinase c-Abl and SR-Rich protein RBM39. Biochem Biophys Res Commun. 2016;473:355\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"598_CR21","doi-asserted-by":"publisher","first-page":"e1005116","DOI":"10.1371\/journal.pgen.1005116","volume":"11","author":"YK Kang","year":"2015","unstructured":"Kang YK, Putluri N, Maity S, Tsimelzon A, Ilkayeva O, Mo Q, et al. CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-\u03b1-Gabpa and stress-induced adaptive responses via NF-\u03baB-cMYC. PLoS Genet. 2015;11:e1005116.","journal-title":"PLoS Genet"},{"key":"598_CR22","doi-asserted-by":"crossref","unstructured":"Kumar PP, Emechebe U, Smith R, Franklin S, Moore B, Yandell M, et al. Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex. eLife. 2014;3:e02805.","DOI":"10.7554\/eLife.02805"},{"key":"598_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","volume":"142","author":"MJ Moore","year":"2010","unstructured":"Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell 2010;142:625\u201336.","journal-title":"Cell"},{"key":"598_CR24","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41418-018-0231-3","volume":"26","author":"C Di","year":"2019","unstructured":"Di C, Syafrizayanti, Zhang Q, Chen Y, Wang Y, Zhang X, et al. Function, clinical application, and strategies of pre-mRNA splicing in cancer. Cell Death Differ. 2019;26:1181\u201394.","journal-title":"Cell Death Differ"},{"key":"598_CR25","first-page":"497","volume":"72","author":"GA Stepanyuk","year":"2016","unstructured":"Stepanyuk GA, Serrano P, Peralta E, Farr CL, Axelrod HL, Geralt M, et al. UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex. Acta Cryst. 2016;72:497\u2013511.","journal-title":"Acta Cryst"},{"key":"598_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2009-10-10-242","volume":"10","author":"PJ Shepard","year":"2009","unstructured":"Shepard PJ, Hertel KJ. The SR protein family. Genome Biol. 2009;10:242.","journal-title":"Genome Biol"},{"key":"598_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1083\/jcb.200710051","volume":"181","author":"JD Ellis","year":"2008","unstructured":"Ellis JD, Ll\u00e8res D, Denegri M, Lamond AI, C\u00e1ceres JF. Spatial mapping of splicing factor complexes involved in exon and intron definition. J Cell Biol. 2008;181:921\u201334.","journal-title":"J Cell Biol"},{"key":"598_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bbagrm.2009.06.002","volume":"1789","author":"JR Prigge","year":"2009","unstructured":"Prigge JR, Iverson SV, Siders AM, Schmidt EE. Interactome for auxiliary splicing factor U2AF(65) suggests diverse roles. Biochim Biophys Acta. 2009;1789:487\u201392.","journal-title":"Biochim Biophys Acta"},{"key":"598_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","volume":"13","author":"T Uehara","year":"2017","unstructured":"Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, et al. Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides. Nat Chem Biol. 2017;13:675\u201380.","journal-title":"Nat Chem Biol"},{"key":"598_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.molcel.2005.07.014","volume":"19","author":"S Sharma","year":"2005","unstructured":"Sharma S, Falick AM, Black DL. Polypyrimidine tract binding protein blocks the 5\u2019 splice site-dependent assembly of U2AF and the prespliceosomal E complex. Mol Cell. 2005;19:485\u201396.","journal-title":"Mol Cell"},{"key":"598_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/humu.22002","volume":"33","author":"A Nordin","year":"2012","unstructured":"Nordin A, Larsson E, Holmberg M. The defective splicing caused by the ISCU intron mutation in patients with myopathy with lactic acidosis is repressed by PTBP1 but can be derepressed by IGF2BP1. Hum Mutat. 2012;33:467\u201370.","journal-title":"Hum Mutat"},{"key":"598_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep28210","volume":"6","author":"N Faherty","year":"2016","unstructured":"Faherty N, Benson M, Sharma E, Lee A, Howarth A, Lockstone H, et al. Negative autoregulation of BMP dependent transcription by SIN3B splicing reveals a role for RBM39. Sci Rep. 2016;6:28210.","journal-title":"Sci Rep"},{"key":"598_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/jcb.20725","volume":"97","author":"F Mart\u00ednez-Arribas","year":"2006","unstructured":"Mart\u00ednez-Arribas F, Agudo D, Poll\u00e1n M, G\u00f3mez-Esquer F, D\u00edaz-Gil G, Lucas R, et al. Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. J Cell Biochem. 2006;97:1275\u201382.","journal-title":"J Cell Biochem"},{"key":"598_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/15384101.2020.1711579","volume":"19","author":"SD Chilewski","year":"2020","unstructured":"Chilewski SD, Bhosale D, Dees S, Hutchinson I, Trimble R, Pontiggia L, et al. Development of CAPER peptides for the treatment of triple negative breast cancer. Cell Cycle. 2020;19:432\u201347.","journal-title":"Cell Cycle"},{"key":"598_CR35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2353\/ajpath.2009.080882","volume":"174","author":"I Mercier","year":"2009","unstructured":"Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, et al. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol. 2009;174:1172\u201390.","journal-title":"Am J Pathol"},{"key":"598_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424\u201347.","journal-title":"Blood"},{"key":"598_CR37","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/j.celrep.2016.07.058","volume":"16","author":"KR Katsumura","year":"2016","unstructured":"Katsumura KR, Ong IM, DeVilbiss AW, Sanalkumar R, Bresnick EH. GATA factor-dependent positive-feedback circuit in acute myeloid leukemia cells. Cell Rep. 2016;16:2428\u201341.","journal-title":"Cell Rep"},{"key":"598_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497\u2013504.","journal-title":"Nat Med"},{"key":"598_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ccell.2019.02.013","volume":"35","author":"R Thomas","year":"2019","unstructured":"Thomas R, Majeti R. No matter how you splice it, RBM39 inhibition targets spliceosome mutant AML. Cancer Cell. 2019;35:337\u20139.","journal-title":"Cancer Cell"},{"key":"598_CR40","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3389\/fonc.2019.00692","volume":"9","author":"S Saha","year":"2019","unstructured":"Saha S, Murmu KC, Biswas M, Chakraborty S, Basu J, Madhulika S, et al. Transcriptomic analysis identifies RNA binding proteins as putative regulators of myelopoiesis and leukemia. Front Oncol. 2019;9:692.","journal-title":"Front Oncol"},{"key":"598_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","volume":"35","author":"E Wang","year":"2019","unstructured":"Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell. 2019;35:369\u201384.e7.","journal-title":"Cancer Cell"},{"key":"598_CR42","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1038\/sj.onc.1205480","volume":"21","author":"CS Bangur","year":"2002","unstructured":"Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene 2002;21:3814\u201325.","journal-title":"Oncogene"},{"key":"598_CR43","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","volume":"75","author":"P Maiso","year":"2015","unstructured":"Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75:2071\u201382.","journal-title":"Cancer Res"},{"key":"598_CR44","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3324\/haematol.2019.218289","volume":"105","author":"J Tong","year":"2020","unstructured":"Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, et al. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica 2020;105:1630\u201340.","journal-title":"Haematologica"},{"key":"598_CR45","doi-asserted-by":"publisher","first-page":"16985","DOI":"10.18632\/oncotarget.7707","volume":"7","author":"L Dai","year":"2016","unstructured":"Dai L, Peng XX, Tan EM, Zhang JY. Tumor-associated antigen CAPER\u03b1 and microvessel density in hepatocellular carcinoma. Oncotarget 2016;7:16985\u201395.","journal-title":"Oncotarget"},{"key":"598_CR46","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2011-301153","volume":"61","author":"AH Sillars-Hardebol","year":"2012","unstructured":"Sillars-Hardebol AH, Carvalho B, Tijssen M, Beli\u00ebn JA, de Wit M, Delis-van Diemen PM, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut. 2012;61:1568\u201375.","journal-title":"Gut"},{"key":"598_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305\u20139.","journal-title":"Science"},{"key":"598_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 2015;523:183\u20138.","journal-title":"Nature"},{"key":"598_CR49","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.str.2019.10.005","volume":"27","author":"X Du","year":"2019","unstructured":"Du X, Volkov OA, Czerwinski RM, Tan H, Huerta C, Morton ER, et al. Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820. Structure. 2019;27:1625\u201333.e3.","journal-title":"Structure"},{"key":"598_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"598_CR51","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376\u201381.","journal-title":"Science"},{"key":"598_CR52","doi-asserted-by":"crossref","unstructured":"Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting TC, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017;356:eaal3755.","DOI":"10.1126\/science.aal3755"},{"key":"598_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","volume":"16","author":"DE Bussiere","year":"2020","unstructured":"Bussiere DE, Xie L, Srinivas H, Shu W, Burke A, Be C, et al. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nat Chem Biol. 2020;16:15\u201323.","journal-title":"Nat Chem Biol"},{"key":"598_CR54","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.celrep.2019.09.079","volume":"29","author":"TC Ting","year":"2019","unstructured":"Ting TC, Goralski M, Klein K, Wang B, Kim J, Xie Y, et al. Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4-DCAF15. Cell Rep. 2019;29:1499\u2013510.e6.","journal-title":"Cell Rep"},{"key":"598_CR55","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1021\/jm9902638","volume":"42","author":"T Owa","year":"1999","unstructured":"Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem. 1999;42:3789\u201399.","journal-title":"J Med Chem"},{"key":"598_CR56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1023\/A:1010608317361","volume":"19","author":"K Fukuoka","year":"2001","unstructured":"Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs. 2001;19:219\u201327.","journal-title":"Invest New Drugs"},{"key":"598_CR57","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/S0959-8049(01)00275-1","volume":"37","author":"Y Ozawa","year":"2001","unstructured":"Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001;37:2275\u201382.","journal-title":"Eur J Cancer"},{"key":"598_CR58","doi-asserted-by":"publisher","first-page":"103545","DOI":"10.1016\/j.jprot.2019.103545","volume":"210","author":"X Jia","year":"2020","unstructured":"Jia X, Pan L, Zhu M, Hu H, Zhai L, Liu J, et al. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate. J Proteom. 2020;210:103545.","journal-title":"J Proteom"},{"key":"598_CR59","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.31398","volume":"124","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2018;124:2758\u201365.","journal-title":"Cancer"},{"key":"598_CR60","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1023\/A:1012287111922","volume":"12","author":"CJ Punt","year":"2001","unstructured":"Punt CJ, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M, et al. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol.2001;12:1289\u201393.","journal-title":"Ann. Oncol."},{"key":"598_CR61","first-page":"5195","volume":"9","author":"C Dittrich","year":"2003","unstructured":"Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res. 2003;9:5195\u2013204.","journal-title":"Clin Cancer Res"},{"key":"598_CR62","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-06-0249","volume":"13","author":"DC Talbot","year":"2007","unstructured":"Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2007;13:1816\u201322.","journal-title":"Clin Cancer Res"},{"key":"598_CR63","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1349-7006.2005.00109.x","volume":"96","author":"Y Yamada","year":"2005","unstructured":"Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, et al. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci. 2005;96:721\u20138.","journal-title":"Cancer Sci"},{"key":"598_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.htct.2018.07.003","volume":"41","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Cruso\u00e9 EQ, Bittencourt RI, Maiolino A, Magalh\u00e3es RJP, Sobrinho JDN, et al. New proteasome inhibitors in the treatment of multiple myeloma. Hematol Transfus Cell Ther. 2019;41:76\u201383.","journal-title":"Hematol Transfus Cell Ther"},{"key":"598_CR65","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"598_CR66","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732\u20136.","journal-title":"Nature"},{"key":"598_CR67","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11523-018-0603-0","volume":"13","author":"L Swift","year":"2018","unstructured":"Swift L, Jayanthan A, Ruan Y, Anderson R, Boklan J, Trippett T, et al. Targeting the proteasome in refractory pediatric leukemia cells: characterization of effective cytotoxicity of carfilzomib. Target Oncol. 2018;13:779\u201393.","journal-title":"Target Oncol"},{"key":"598_CR68","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma. Blood 2014;123:1461\u20139.","journal-title":"Blood"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00598-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:51:42Z","timestamp":1669974702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00598-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1038\/s41420-021-00598-7","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}